TransMedics Group(NASDAQ) TMDX

TransMedics Group, Inc. helps doctors keep donor organs alive during transport. This technology replaces the standard method of keeping organs on ice. It helps more patients receive life-saving transplants.

From Machines to Managed Services

• OCS Liver: Portable system designed to maintain donor livers in near-physiological conditions using specialized perfusion technology.
• OCS Heart: Device used for the extracorporeal perfusion and maintenance of donor hearts outside the human body.
• OCS Lung: Module used to preserve and monitor donor lungs for double-lung transplants.
• National OCS Program: Solution providing outsourced organ procurement, clinical management, and transplant logistics.
• Transplant Logistics: Services including aviation and ground transportation to coordinate the delivery of donor organs.

Scaling the National Logistics Network

• Obtained Pre-Market Approval from the FDA for heart, lung, and liver perfusion systems.
• Purchased transplant aircraft to support aviation transportation for the National OCS Program.
• Commenced a finance lease for a new global headquarters in Somerville, Massachusetts, in Jan. 2026.
• Secured CE mark recertification for heart and lung systems under European Union regulations in Sept. 2022.
• Obtained a Class II Medical Device License for the OCS Liver system from Health Canada in Oct. 2023.

One of a Kind Technology

TransMedics operates the only portable, multi-organ, warm perfusion technology platform with FDA approval. The company integrates its proprietary technology with a national logistics network to improve organ procurement efficiency across the United States.

Checking the Vital Signs

• Total revenue was $189.9 million for the three-month period ended June 30, 2026.
• Revenue from United States customers reached $350.6 million for the six-month period ended June 30, 2026, up $59.8 million year over year.
• Net income was $22.0 million for the six-month period ended June 30, 2026.
• Cash and cash equivalents reached $472.7 million as of June 30, 2026.
• Market capitalization was $2.8 billion with a P/E ratio of 39.5 based on recent market data.

Bottom Line

TransMedics has evolved from a medical device developer into an integrated provider of transplant technology and logistics. This transition from static storage to a managed service model aims to increase the supply of transplantable organs.